METHODS
BLOOD
Detailed methods of this randomized, double-blinded, controlled, Phase 2 trial were published previously [Families were informed about the study and provided written informed consent in a private area before enrollment and venipuncture. Blood was drawn at baseline (Day 0), 28 days, and for participants whose parent/guardian could be recontacted and provided consent for an additional collection, 30–35 months after vaccination. Serum was tested for anti-Vi IgG and IgA antibodies using a commercially available enzyme-linked immunosorbent assay (ELISA) kit, VaccZyme 